Drug Discovery World
APRIL 21, 2023
New study results have demonstrated the potential of a new drug to reprogramme the immune profile in the tumour microenvironment (TME) and convert resistant tumours to responders to Immune Checkpoint Blockage (ICB) therapies. Purple Biotech shared the new results at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Florida, US.
Drug Hunter
APRIL 20, 2023
We asked the global drug discovery community to nominate and vote on their favorite molecule from 2022, and the results are in. The 2022 winner, with the most overall votes across the ten finalist molecules , is BMS’ oral, deuterated allosteric TYK2 inhibitor, deucravacitinib, the first new treatment for plaque psoriasis in nearly a decade. Here, we highlight what makes deucravacitinib so impressive to the drug discovery community.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery Today
APRIL 20, 2023
Global integrated drug discovery company, Sygnature Discovery and global healthcare group Daewoong Pharmaceutical, have entered into a research collaboration agreement to accelerate the discovery of a novel small molecule to target autoimmune disease.
Chemical Biology and Drug Design
APRIL 20, 2023
The design of in silico and in vitro study. Abstract Colorectal cancer (CRC) is the second most common cancer in women and the third most common in men worldwide. Impaired cell cycle regulation leads to many cancers and is also approved in CRC. Therefore, cell cycle regulation is a critical therapeutic target for CRC. Furthermore, miRNAs have been discovered as regulators in a variety of cancer-related pathways.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Discovery World
APRIL 20, 2023
Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. We are amidst a shift of focus from dealing with the acute impacts of the Covid-19 pandemic to tackling the ‘long Covid-19’ symptoms that may now represent greater future challenges for healthcare systems and patient quality of life.
Antidote
APRIL 17, 2023
Homocystinuria, an inherited disorder, is a rare metabolic condition that impacts 1 in 335,000 people worldwide and is present from birth. Often abbreviated as HCU or HCY, homocystinuria is a genetic disorder that inhibits the body from processing certain amino acids found in proteins, causing a harmful buildup of homocysteine and methionine.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Chemical Biology and Drug Design
APRIL 19, 2023
Novel class of procaine-embedded thiazole-pyrazole derivatives were developed as a potent and selective inhibitor of DPP-4 and NF-ĸB. Among the series developed, the most potent inhibitor compound 8i inhibits STZ-induced complications of diabetic nephropathy as evidenced by improvement in the major biochemical parameter. It showed improvement of liver function and kidney function in rats with reduction of oxidative stress and inflammation in rats.
Drug Discovery World
APRIL 19, 2023
Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Under a new strategic research collaboration, an ICR team led by Professor Chris Lord will investigate the effect of NeoPhore’s inhibitors on tumours in the laboratory. The inhibitors are small molecules that target proteins involved in DNA mismatch repair (MMR), an important process in cells that corrects mistakes that are
Drug Patent Watch
APRIL 19, 2023
This article was originally published by Jiayi Chen, Zhifeng Zhao, Xinyu Wang and Jingjun Huang in Drug Repurposing – Advances, Scopes and Opportunities in Drug Discovery and is republished here… The post Utilizing 505(b)(2) Regulatory Pathway for New Drug Applications: An Overview on the Advanced Formulation Approach and Challenges appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
APRIL 18, 2023
The home of the UK’s lab industry expands floor plan to accommodate increased interest in this year’s show
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Chemical Biology and Drug Design
APRIL 19, 2023
This study demonstrates the potential of sclerotiorin isolated from Penicillium mallochii to inhibit acetylcholinesterase. The compound prevents the breakdown of acetylcholine and thereby increases the duration of neurotransmitter in the receptor, eventually helping in improved memory. Abstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder caused due to the damage and loss of neurons in specific brain regions.
Drug Discovery World
APRIL 18, 2023
Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. While the global proteasome inhibitors market is expected to reach nearly $2.3 billion by 2026, these drugs are primarily indicated for the treatment of multiple
Drug Channels
APRIL 18, 2023
Like it or not, the Centers for Medicare & Medicaid Services (CMS) is barreling ahead with its implementation of the Inflation Reduction Act of 2022 (IRA). Last Friday was the last day to submit comments on CMS's initial guidance on the drug price negotiation program. The IRA will alter many crucial aspects of the Medicare program and the overall drug channel.
Drug Discovery Today
APRIL 21, 2023
Domainex is honoured to announce it has received a King’s Award for Enterprise: International Trade 2023.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Chemical Biology and Drug Design
APRIL 18, 2023
Herein, we report a novel class of NSD3 histone methyltransferase inhibitor. Our inhibitor ( 13i ) was predicted to show showed a unique, bivalent binding mode interacting with both SAM-binding site and BT3-bindig site within the SET domain. Its in vitro activity and cellular activity were validated. Abstract NSD3/WHSC1L1 lysine methyltransferase promotes the transcription of target genes through di- or tri-methylation at histone H3K36 using SAM as a cofactor.
Drug Discovery World
APRIL 21, 2023
News round-up for 16-21 April by DDW Digital Content Editor Diana Spencer. The news stories dominating the headlines this week have been the breaking developments in cancer drug discovery announced at the American Association of Cancer Research (AACR) Annual Meeting, which was held in Florida, US from 14-19 April. The event showcased the very latest innovations in cancer therapies, from personalised mRNA vaccines to bispecific antibodies.
FDA Law Blog: Biosimilars
APRIL 19, 2023
By Deborah L. Livornese — Last week FDA checked off another item on its to-do list for implementing the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) OTC monograph reform provisions. As provided in the OMUFA Performance Goals letter , FDA issued draft guidance on the content and format of submissions. The draft guidance for industry entitled Over-the-Counter Monograph Order Requests (OMORs): Format and Content , outlines the information (content) and the form of and manner in
Drug Patent Watch
APRIL 21, 2023
Annual Drug Patent Expirations for NEXLETOL Nexletol is a drug marketed by Esperion Theraps Inc and is included in one NDA. It is available from one supplier. There are six… The post New patent for Esperion Theraps drug NEXLETOL appeared first on DrugPatentWatch - Make Better Decisions.
Chemical Biology and Drug Design
APRIL 18, 2023
Protective effects and mechanism of Paecilomyces cicadae TJJ1213 intracellular polysaccharide against H 2 O 2 -induced PC12 cells damage. Abstract Oxidative stress is a key process in the development of neurodegenerative diseases. More attention is needed to screen natural antioxidants and explore pharmacological mechanisms. Natural product polysaccharides with no toxic side effects have powerful antioxidant activity.
Drug Discovery World
APRIL 21, 2023
Tisch Cancer Center scientists have developed unique models of acute myeloid leukaemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. The research was presented at the annual meeting of the American Association of Cancer Research and simultaneously published in Blood Cancer Discovery , a journal of the American Association for Cancer Research.
FDA Law Blog: Biosimilars
APRIL 18, 2023
By Larry K. Houck — In addition to regulating drugs of abuse, the federal Controlled Substances Act (“CSA”) controls the manufacture and distribution of chemicals used in the illicit manufacture of controlled substances. As the primary agency enforcing the CSA, the Drug Enforcement Administration (“DEA”) previously designated nine chemicals used in the illicit manufacture of fentanyl or its analogues as List I or List II chemicals.
Drug Patent Watch
APRIL 21, 2023
Annual Drug Patent Expirations for TAVNEOS Tavneos is a drug marketed by Chemocentryx and is included in one NDA. It is available from one supplier. There are two patents protecting… The post New patent for Chemocentryx drug TAVNEOS appeared first on DrugPatentWatch - Make Better Decisions.
Chemical Biology and Drug Design
APRIL 18, 2023
The severity of chagas disease remains a major concern in endemic areas and an emerging public health hazard in nonendemic countries. Trypanosoma cruzi , the etiological agent of this NTD, is mostly transmitted by triatomine vectors and comprises a range of epidemiologically significant variants. Abstract Twenty different infectious disorders induced by bacteria, viruses, and parasites are categorized as neglected tropical diseases (NTDs) by WHO.
Drug Discovery World
APRIL 21, 2023
Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on 10 May at 8AM PST | 11AM EST | 4PM BST | 5PM CET. Join this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy. In this free webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe D
Crucial Data Solutions
APRIL 21, 2023
How easy to use is your eClinical software for front-end users (participants and site team members) and for back-end users who build and manage the studies? Let's break down the reasons why this is such an important consideration in this blog post. The post One Key to Choosing the Best eClinical Technology Vendor: Great Partners Keep It Simple appeared first on Crucial Data Solutions.
Drug Patent Watch
APRIL 21, 2023
Annual Drug Patent Expirations for NEXLIZET Nexlizet is a drug marketed by Esperion Theraps Inc and is included in one NDA. It is available from one supplier. There are seven… The post New patent for Esperion Theraps drug NEXLIZET appeared first on DrugPatentWatch - Make Better Decisions.
Chemical Biology and Drug Design
APRIL 18, 2023
Role and mechanism of Stat5 in NLRP3-mediated pyroptosis and CR of BC cells. Abstract The treatment of breast cancer (BC) calls for targeted methods to overcome chemoresistance (CR). This study is expected to figure out the mechanism of signal transducer and activator of transcription 5 (STAT5) in NOD-like receptor family pyrin domain containing 3 (NLRP3)-mediated pyroptosis and CR in BC cells.
Drug Discovery World
APRIL 21, 2023
Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET. Join this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy. In this free webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe D
Cytel
APRIL 21, 2023
It was early March 2020, after the world was hit by the Covid-19 pandemic, that those of us on the CDISC Eu committee together with the CDISC team had to make the decision to switch our upcoming CDISC Eu 2020 event from face-to-face to virtual. This was done in less than two months with a very successful outcome, despite the regret of not seeing all our colleagues and friends from all over Europe.
Drug Patent Watch
APRIL 21, 2023
Annual Drug Patent Expirations for VTAMA Vtama is a drug marketed by Dermavant Sci and is included in one NDA. It is available from one supplier. There are four patents… The post New patent for Dermavant Sci drug VTAMA appeared first on DrugPatentWatch - Make Better Decisions.
Chemical Biology and Drug Design
APRIL 16, 2023
A decline in angiogenesis becomes pronounced with increasing age and related to the abnormal function of endothelial cells. Nitric oxide (NO) can counteract endothelial cell senescence and NO donor-based senescent cell scavengers and SASP inhibitors promote angiogenesis. Abstract The decrease in angiogenesis that occurs with aging significantly contributes to the higher incidence and mortality of cardiovascular diseases among the elderly.
Drug Discovery World
APRIL 20, 2023
Monitoring neuronal morphology in long-term in vitro cell cultures is critical for characterisation and evaluation of disease models and to understand neuronal development. Ideally, approaches to track neurite dynamics would allow continuous automated measurements of structural parameters, including neurite length and number of branch points. These methods should be non-perturbing and enable quantification of neurons in mono- or co-culture with glia.
Drug Channels
APRIL 21, 2023
Today’s guest post comes from Ticia Cawley, VP of Client Solutions at ConnectiveRx. Ticia reviews four interim findings from ConnectiveRx's survey of buy-and-bill prescribers and their support staff. The survey reveals new insights about how practices evaluate automation and digital tools for provider-administered specialty therapies. To learn more, register for ConnectiveRx’s free online panel discussion on May 17th at 1:00 p.m.
Crucial Data Solutions
APRIL 21, 2023
Clinical trials require a ton of people power. Further, many facets of clinical trials call for highly specialized help, whether that be process expertise or the ability to provide technology solutions. Few research sponsors and even CROs have teams in place that address every last need for a given trial. This is not to mention that clinical trials, in general, are becoming more complex every day with data coming from a nearly limitless number of sources and pressure to make trials more inclusiv
Expert insights. Personalized for you.
246 
Let's personalize your content